Brokers Issue Forecasts for MNPR FY2025 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Monopar Therapeutics in a research report issued to clients and investors on Monday, July 7th. Cantor Fitzgerald analyst K. Kluska anticipates that the company will post earnings per share of ($1.30) for the year. Cantor Fitzgerald currently has a "Overweight" rating and a $74.00 target price on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. Cantor Fitzgerald also issued estimates for Monopar Therapeutics' FY2026 earnings at ($3.09) EPS.

Several other equities research analysts have also recently commented on the company. Chardan Capital initiated coverage on Monopar Therapeutics in a research note on Monday, June 23rd. They issued a "buy" rating and a $60.00 target price for the company. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Piper Sandler reaffirmed an "overweight" rating and set a $76.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, March 19th. Finally, Jones Trading reaffirmed a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $60.00.

Monopar Therapeutics Price Performance

Shares of NASDAQ MNPR traded down $1.39 during midday trading on Wednesday, hitting $36.87. The stock had a trading volume of 40,442 shares, compared to its average volume of 362,872. The company's 50-day simple moving average is $35.55 and its 200 day simple moving average is $35.61. The firm has a market cap of $225.64 million, a P/E ratio of -10.59 and a beta of 1.01. Monopar Therapeutics has a fifty-two week low of $1.72 and a fifty-two week high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.27.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Janus Henderson Group PLC acquired a new position in Monopar Therapeutics in the fourth quarter valued at about $23,435,000. Adage Capital Partners GP L.L.C. acquired a new position in Monopar Therapeutics in the fourth quarter valued at about $13,182,000. RA Capital Management L.P. acquired a new position in Monopar Therapeutics in the fourth quarter valued at about $11,247,000. Point72 Asset Management L.P. acquired a new position in Monopar Therapeutics in the fourth quarter valued at about $3,694,000. Finally, ADAR1 Capital Management LLC acquired a new position in Monopar Therapeutics in the fourth quarter valued at about $2,861,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.